Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTOG 0241 A PHASE I STUDY OF IRINOTECAN AND CISPLATIN IN COMBINATION WITH TWICE DAILY THORACIC RADIOTHERAPY (45 GyOR ONCE DAILY THORACIC RADIOTHERAPY(70 Gy) FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER).

Trial Profile

RTOG 0241 A PHASE I STUDY OF IRINOTECAN AND CISPLATIN IN COMBINATION WITH TWICE DAILY THORACIC RADIOTHERAPY (45 GyOR ONCE DAILY THORACIC RADIOTHERAPY(70 Gy) FOR PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER).

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Cisplatin
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jun 2009 New source identified and integrated (New Jersey Cancer Trial Connect).
    • 30 Jun 2009 Additional lead trial investigator Hageboutros A identified as reported by New Jersey Cancer Trial Connect.
    • 04 Nov 2008 Checked against ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top